The facility integrates advanced scientific infrastructure and specialised workflows to support complex drug delivery systems, sterile injectables, and differentiated dosage forms
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
